Form 8-K Pacira Pharmaceuticals, For: Mar 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Pacira Pharmaceuticals (PCRX) Data 'Increases Takeout Valuation' - Mizuho
March 1, 2017 10:30 AM ESTShares of Pacira Pharmaceuticals (NASDAQ: PCRX) are up 12% following positive Phase IV data from the TKA study. The study hit both of its co-primary endpoints (demonstrating statistically significant benefits for greater pain reduction (p=0.0381) and lower opioid utilization (p=0.0048). Secondary endpoints such as... More
